Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07833046 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Long-term Follow-up Study in Subjects With Multiple Myeloma Previously Treated With GC012F Injection

StatusNot Yet Recruiting
PhaseNot specified
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study First Submitted
RenJi Hospital
190 trials monitored
See 2 trials at risk
Multiple Myeloma
1,261 trials monitored
See 80 trials at risk
This is an open-label, multicenter, observational study (non-interventional study) to evaluate the long-term safety, efficacy, and in vivo pharmacokinetic persistence of CAR-T cells in subjects treated with GC012F Injection
Trial Details
NCT Number NCT07833046
Lead Sponsor RenJi Hospital
Collaborators: Gracell Biotechnologies (Shanghai) Co., Ltd., AstraZeneca Global R&D (China) Co., Ltd., AstraZeneca Global R&D (Beijing) Co., Ltd.
Conditions
(from sponsor)		 Multiple Myeloma
Related terms Multiple Myeloma
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov